inclusion criteria: * documented informed consent of the participant and/or legally authorized representative * age: \>= 18 years * eastern cooperative oncology group (ecog) =\< 1 * histologically confirmed diagnosis of cll according to world health organization (who) classification * prior covid-19 vaccination (2 or more pfizer or moderna) with last injection \>= 3 months prior * fully recovered from the acute toxic effects (except alopecia) to =\< grade 1 to prior anti-cancer therapy * white blood cells (wbc) \>= 1,000/mm\^3 (to be performed within 14 days prior to day 1 of protocol therapy) * platelets \>= 50,000/mm\^3 (to be performed within 14 days prior to day 1 of protocol therapy) * total bilirubin =\< 1.5 x upper limit of normal (uln) (unless has gilbert's disease) (to be performed within 14 days prior to day 1 of protocol therapy) * aspartate aminotransferase (ast) =\< 2.5 x uln (to be performed within 14 days prior to day 1 of protocol therapy) * alanine transaminase (alt) =\< 2.5 x uln (to be performed within 14 days prior to day 1 of protocol therapy) * creatinine clearance \<1.5 uln (to be performed within 14 days prior to day 1 of protocol therapy) * women of childbearing potential (wocbp): negative urine or serum pregnancy test (to be performed within 14 days prior to day 1 of protocol therapy) * if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required * agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last vaccine injection * childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)

inclusion criteria: * documented informed consent of the participant and/or legally authorized representative * age: \>= 18 years * eastern cooperative oncology group (ecog) =\< 1 * histologically confirmed diagnosis of cll according to world health organization (who) classification * prior covid-19 vaccination (2 or more pfizer or moderna) with last injection \>= 3 months prior * fully recovered from the acute toxic effects (except alopecia) to =\< grade 1 to prior anti-cancer therapy * white blood cells (wbc) \>= 1,000/mm\^3 (to be performed within 14 days prior to day 1 of protocol therapy) * platelets \>= 50,000/mm\^3 (to be performed within 14 days prior to day 1 of protocol therapy) * total bilirubin =\< 1.5 x upper limit of normal (uln) (unless has gilbert's disease) (to be performed within 14 days prior to day 1 of protocol therapy) * aspartate aminotransferase (ast) =\< 2.5 x uln (to be performed within 14 days prior to day 1 of protocol therapy) * alanine transaminase (alt) =\< 2.5 x uln (to be performed within 14 days prior to day 1 of protocol therapy) * creatinine clearance \<1.5 uln (to be performed within 14 days prior to day 1 of protocol therapy) * women of childbearing potential (wocbp): negative urine or serum pregnancy test (to be performed within 14 days prior to day 1 of protocol therapy) * if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required * agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last vaccine injection * childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)

inclusion criteria: documented informed consent of the participant and/or legally authorized representative age: >= 18 years eastern cooperative oncology group (ecog) =< 1 histologically confirmed diagnosis of cll according to world health organization (who) classification prior covid-19 vaccination (2 or more pfizer or moderna) with last injection >= 3 months prior fully recovered from the acute toxic effects (except alopecia) to =< grade 1 to prior anti-cancer therapy white blood cells (wbc) >= 1,000/mm^3 (to be performed within 14 days prior to day 1 of protocol therapy) platelets >= 50,000/mm^3 (to be performed within 14 days prior to day 1 of protocol therapy) total bilirubin =< 1.5 x upper limit of normal (uln) (unless has gilbert's disease) (to be performed within 14 days prior to day 1 of protocol therapy) aspartate aminotransferase (ast) =< 2.5 x uln (to be performed within 14 days prior to day 1 of protocol therapy) alanine transaminase (alt) =< 2.5 x uln (to be performed within 14 days prior to day 1 of protocol therapy) creatinine clearance <1.5 uln (to be performed within 14 days prior to day 1 of protocol therapy) women of childbearing potential (wocbp): negative urine or serum pregnancy test (to be performed within 14 days prior to day 1 of protocol therapy) if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last vaccine injection childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

inclusion criteria: documented informed consent of the participant and/or legally authorized representative age: >= 18 years eastern cooperative oncology group (ecog) =< 1 histologically confirmed diagnosis of cll according to world health organization (who) classification prior covid-19 vaccination (2 or more pfizer or moderna) with last injection >= 3 months prior fully recovered from the acute toxic effects (except alopecia) to =< grade 1 to prior anti-cancer therapy white blood cells (wbc) >= 1,000/mm^3 (to be performed within 14 days prior to day 1 of protocol therapy) platelets >= 50,000/mm^3 (to be performed within 14 days prior to day 1 of protocol therapy) total bilirubin =< 1.5 x upper limit of normal (uln) (unless has gilbert's disease) (to be performed within 14 days prior to day 1 of protocol therapy) aspartate aminotransferase (ast) =< 2.5 x uln (to be performed within 14 days prior to day 1 of protocol therapy) alanine transaminase (alt) =< 2.5 x uln (to be performed within 14 days prior to day 1 of protocol therapy) creatinine clearance <1.5 uln (to be performed within 14 days prior to day 1 of protocol therapy) women of childbearing potential (wocbp): negative urine or serum pregnancy test (to be performed within 14 days prior to day 1 of protocol therapy) if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last vaccine injection childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)